1. Lizza EF, Rosen RC. Definition and classification of erectile dysfunction: Report of the Nomenclature Committee of the International Society of Impotence Research. Int J Impot Res 1999; 11: 141–3.
2. Kaufman JM, Vermeulen A. Declining gonadal function in elderly men. Baillieres Clin Endocrinol Metab 1997; 11: 289–309.
3. Ferrini RL, Barrett-Connor E. Sex hormones and age: A cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 1998; 147: 750–4.
4. Morley JE, Kaiser FE, Perry HM et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410–3.
5. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male 2002; 5 (2): 98–102.
6. Дедов И.И, Калинченко С.Ю. Возрастной андрогенный дефицит у мужчин. Практич. мед., 2006.
7. Gray A, Feldman HA, McKinlay JB, Longcope С. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016–25.
8. Guay AT, Velasquez E, Perez JB. Characterization of patients in a medical endocrine-based center for male sexual dysfunction. Endocr Pract 1999; 5: 314–21.
9. Dhindsa S, Prabhakar S, Sethi M et al. Frequent occurrence of hypogo-nadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 5462–8.
10. Betancourt-Albrecht M, Cunningham GR. Hypogonadism and diabetes. Int J Impot Res 2003; 15 (Suppl. 4): S14–20.
11. Harman SM, Metter EJ, Tobin JD et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724–31.
12. Hatzichristou D, Hatzimouratidis K, Bekas M et al. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol 2002; 168: 615–20.
13. Korenman SG, Morley JE, Mooradian AD et al. Secondary hypogonadism in older men: Its relation to impotence. J Clin Endocrinol Metab 1990; 71: 963–9.
14. Aversa A, Bruzziches R, Greco EA et al. Possible involvement of gonadic steroids in determining erectile response to pharmacoerection test in men with erectile dysfunction. It J Sex Reprod Med 2006; 13: 3–9.
15. Travison TG, Morley JE, Araujo AB et al. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab 2006; 91 (7): 2509–13.
16. Traish AM, Goldstein I, Kim NN. Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. European Urology 2007; 52: 54–70.
17. Zhang X-H, Morelli A, Luconi M et al. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 2005; 47: 409–16.
18. Shen ZJ, Zhou XL, Lu YL et al. Effect of androgen deprivation on penile ultrastructure. Asian J Androl 2003; 5: 33–6.
19. Traish AM, Toselli P, Jeong SJ et al. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for venoocclusive dysfunction in androgen deficiency. J Androl 2005; 26: 242–8.
20. Armagan A, Kim NN, Goldstein I et al. Dose-response relationship between testosterone and erectile function: evidence for the existence of a critical threshold. J Androl 2006; 27: 517–26.
21. Meusburger SM, Keast JR. Testosterone and nerve growth factor have distinct but interacting effects on structure and neurotransmitter expression of adult pelvic ganglion cells in vitro. Neuroscience 2001; 108: 331–40.
22. Rogers RS, Graziottin TM, Lin CM et al. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-assoicated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003; 15: 26–37.
23. Hwang TS, Chen HE, Tsai TF, Lin YC. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res 2006; 18: 400–4.
24. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658–63.
25. Aversa A, Isidori AM, De Martino MU. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilatation in men with erectile dysfunction. Clin Endocrinol 2000; 53: 517–22.
26. Mills TM, Reilly CM, Lewis RW. Androgens and penile erection: a review. J Androl 1996; 17: 633–8.
27. Малая Л.Т., Корж А.Н., Балковая Л.Б. Эндотелиальная дисфункция при патологии сердечно-сосудистой системы. Харьков: ТОРСИНГ, 2000.
28. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153–7.
29. Musuda H, Tsujii T, Okuno T et al. Accumulated endogenous NOS inhibitors, decreased NOS activity, and impaired cavernosal relaxation with ischemia. Am J Physiol Regul Integr Comp Physiol 2002; 282: R1730–8.
30. Maas R, Wenske S, Zabel M et al. Elevation of Asymmetrical Dimethylarginine (ADMA) and Coronary Artery Disease in Men with Erectile Dysfunction. Eur Urol 2005; 48: 1004–12.
31. Graham M, Daly L, Refsum H et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA 1997; 277 (22): 1775–81.
32. McQuillan BM, Beilby JP, Nidorf M, Thompson PL. Hyperhomocysteinemia but not the C677T mutation of MTHFR is an independent risk determinant of carotid wall thickening. Circulation 1999; 99: 2383–8.
33. Bots M, Launer L, Lindemans J et al. Homocysteine and short–term risk of myocardial infarction and stroke in the elderly. The Rotterdam Study. Arch Intern Med 1999; 159: 38.
34. Fu W, Dudman N, Perry M, Wang X. Homocysteinemia attenuates hemodynamic responses to nitric oxide in vivo. Atherosclerosis 2002; 161 (1): 169–76.
35. Lang D, Kredan MB, Lang D et al. Homocysteine – induced inhibition of endothelium–dependent relaxation in rabbit aorta: Role for superoxide anions. Arterioscler Thromb Vasc Biol, 2000; 20(2) 422–7.
36. Billups KL, Kaiser DR, Kelly AS et al. Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with ED. Int J Impot Res 2003; 15 (4): 231–6.
37. Ridker PM, Danielson E, Rifai N et al. Blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006; 48: 73–9.
38. Stellato RK, Feldman HA, Hamdy O et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23 (4): 490–4.
39. Schroeder ET, Zheng L, Ong MD et al. Effects of androgen therapy on adipose tissue and metabolism in older men. J Clin Endocrinol Metab 2004; 89 (10): 4863–72.
40. Liu PY, Wishart SM, Celermajer DS et al. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol 2003; 148 (l): 55–66.
41. Celermajer DS, Sorensen KE, Georgakopoulos D et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88: 2149–55.
42. Sasaki S, Higashi Y, Nakagawa K et al. A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension. Am J Hypertens 2002; 15: 302–9.
43. Hamdy O, Ledbury S, Mullooly C et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003; 26: 2119–25.
44. Niskanen L, Laaksonen DE, Punnonen K et al. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004; 6: 208–15.
45. Ganz P, Vita JA. Testing endothelial vasomotor function. Nitric oxide, a multipotent molecule. Circulation 2003; 108: 2049–53.
46. Doshi SN, McDowell IF, Moat SJ et al. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol 2001; 21: 1196–202.
47. Korantzopoulos P, Galaris D. The protective role of vitamin C on endothelial dysfunction. J Clin Basic Cardiol 2003; 6: 3–5.
48. Brattstrom L, Israelsson B, Jeppson J-O et al. Folic acid – an innocuons means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988; 48: 215–21.
49. Padma-Nathan H, Christ G, Adaikan G et al. Pharmacotherapy for erectile dysfunction. J Sex Med 2004; 1: 128–40. Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Cur Urol Rep 2003; 4: 457–65.
50. Desouza C, Parulkar A, Lumpkin D et al. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002; 25: 1336–9.
51. Katz SD, Balidemaj K, Homma S et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845–51.
52. Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analysis. J Urol 2002; 168: 1332–6.
53. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of Sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002; 60: 12–27.
54. Hatzichristou D, Montorsi F, Buvat J et al. The efficacy and safety of flexible-dose vardenafil (Levitra) in a broad population of European men. Eur Urol 2004; 45: 634–41.
55. Shabsigh R. Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med 2005; 2: 785–92.
56. Aversa A, Isidori AM, Spera G et al. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003; 58: 632–8.
57. Shamloul R, Ghanem H, Fahmy I et al. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med 2005; 2: 559–64.
58. Isidori AM, Giannetta E, Gianfrilli D et al. Effects of testosterone on sexual function in men: results of a metaanalysis. Clin Endocrinol 2005; 63: 381–94.
59. Bagatell CJ, Bremner WJ. Androgens in men – uses and abuses. N Engl J Med 1996; 334: 707–14.
60. Jordan WP. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and non-scrotal transdermal systems. Am J Contact Dermat 1997; 8: 108–13.
61. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol 2006; 65 (3): 275–81.
62. Sokol RZ, Palacios A, Campfield LA et al. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 1982; 37: 425–31.
63. Harle L, Basaria S, Dobs AS. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 2005; 6: 1751–9.
64. Behre HM, Abshagen K, Oettel M et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur Endocrin 1999; 140: 414–9.
65. Yassin AA, Saad F, Traish A Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 2006; 3: 727–35.
66. Tas A, Ersoy A, Ersoy C et al. Efficacy of sildenafil in male dialysis patients with erectile dysfunction unresponsive to erythropoietin and/or testosterone treatments. Int J Impot Res 2006; 18: 61–8.
67. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoato reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003; 6: 94–9.
68. Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. European Urology 2006; 50: 940–7.
69. Rosenthal BD, May NR, Metro MJ et al. Adjunctive use- of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006; 67: 571–4.
70. Ebert T, Jockenhovel F, Morales A, Shabsigh R. The current status of therapy for symptomatic late- onset hypogonadism with transdermal testosterone gel. Eur Urol 2005; 47: 137–46.
71. Hanke H, Lenz C, Hess B et al. Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 2001; 103: 1382–5.
72. Guay AT. Testosterone and erectile physiology. Aging Male 2006; 9 (4): 201–6.
73. Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001; 22: 793–7.

С.И.Гамидов, Е.М.Сотникова,
Т.В.Мехтиев, Д.В.Щербаков